Intravitreal injections course
in practice and clinic

(English or German)

Intravitreal drug delivery has become the gold standard for treating many retinal diseases, first and foremost, neovascular age-related macular degeneration (AMD), diabetic macular oedema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO).
The frequency of intravitreal injections during the day in clinical practice has significantly increased since the introduction of anti-vascular endothelial growth factor (VEGF) medications 18 years ago.
An ageing population due to demographic change, as well as common diseases such as diabetes and cardiovascular complications, are leading to an increased number of patients with retinal diseases that can be effectively treated with anti-VEGF therapies.
The technique of intravitreal injections must be mastered to allow a reliable flow of the daily organisational routine of surgery, sterility and, above all, patient safety.
Nowadays, various products are available on the market (Lucentis®, Eylea®, Beovu®, Ozurdex® and Vabysmo®) that are either injected directly with pre-filled syringes or withdrawn beforehand from glass containers with transfer needles and then applied with injection needles.
Either way, the techniques involved in adequately performing the procedures are essential to master to optimise patient safety and avoid the risk of complications.


Registration and welcome address

IVI substances and indications
PD Dr Hatz, Vista Augenklinik Binningen
Label/off-label Switzerland, costs, approvals, upcoming therapies, overview of treatment regimens

Intravitreal treatments for wet AMD
PD Dr Maria Della Volpe, Augenklinik Heuberger Olten
Guidelines, Diagnostics, Treatment Schemes

Intravitreal treatments for DME and ME after venous occlusion
Dr. Wael Abou Hadeed, Vista Augenklinik Zürich
Guidelines, Diagnostics, Treatment Schemes

Intravitreal treatments for myopic CNV and rare indications
PD Dr Mayss Al-Sheikh, Universitätsspital Zürich
Guidelines, Diagnostics, Treatment Schemes

Recommendations for intravitreal injection
PD Dr Aude Ambresin, RétinElysée Lausanne
Guidelines, injection technique, diagnostics/management of complications

15:50 -16:00


(optional for participants of the theory part, pre-booking necessary)

  • IVI anti-VEGF
  • IVI Ozurdex

Teaching faculty

PD Dr. Katja Hatz Vista Klinik AG
PD Dr Maria Della Volpe Augenklinik Heuberger Olten
Dr Wael Abou Hadeed Vista Augenklinik Zürich
PD Dr Mayss Al-Sheikh Universitätsspital Zürich
PD Dr Aude Ambresin RétinElysée Lausanne
Experts from industry: AbbVie AG, Bayer (Schweiz) AG, Novartis Pharma (Schweiz), AG and Roche Pharma (Schweiz) AG


KKL Kultur- und Kongresszentrum Luzern

Date: 3rd March 2023
Language: English or German
Theory (Deuxième Saal)
Free entry
14:20 – 16:00
Hands on (Clubräume)
Ticket requested
16:00 – 17:30


3rd March 2023
Hands on

16:00 – 17:30
0 seats available!

Members CHF 0
Non Members CHF 100

This training is affiliated with the official programme of the 2023 SAoO Congress.
This event might be videotaped, photographed, and audio-taped. The videos, photographs, and audio recordings may appear either on the SAoO website or the sponsors’ websites, marketing materials in various print or digital formats, and social media platforms.

Für weitere Anfragen wenden Sie sich bitte an

Sponsored by